Tashkin DP[au] - Search Results

Year	Number of Results
1969	1
1971	1
1972	3
1973	2
1974	2
1975	2
1976	2
1977	12
1978	4
1979	10
1980	4
1981	7
1982	13
1983	8
1984	9
1985	6
1986	4
1987	13
1988	14
1989	4
1990	6
1991	11
1992	9
1993	5
1994	8
1995	8
1996	7
1997	14
1998	8
1999	6
2000	7
2001	6
2002	12
2003	8
2004	9
2005	11
2006	15
2007	11
2008	15
2009	18
2010	19
2011	17
2012	17
2013	15
2014	11
2015	22
2016	17
2017	14
2018	17
2019	18
2020	20
2021	16
2022	16

1

Smoking Cessation in Chronic Obstructive Pulmonary Disease.

Tashkin DP. Tashkin DP. Semin Respir Crit Care Med. 2015 Aug;36(4):491-507. doi: 10.1055/s-0035-1555610. Epub 2015 Aug 3. Semin Respir Crit Care Med. 2015. PMID: 26238637 Review.

2

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Khanna D, et al. Among authors: tashkin dp. Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660. doi: 10.1164/rccm.201903-0563CI. Am J Respir Crit Care Med. 2020. PMID: 31841044 Free PMC article.

3

Pulmonary effects of inhaled cannabis smoke.

Tashkin DP, Roth MD. Tashkin DP, et al. Am J Drug Alcohol Abuse. 2019;45(6):596-609. doi: 10.1080/00952990.2019.1627366. Epub 2019 Jul 12. Am J Drug Alcohol Abuse. 2019. PMID: 31298945 Review.

4

Cyclophosphamide versus placebo in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Tashkin DP, et al. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi: 10.1056/NEJMoa055120. N Engl J Med. 2006. PMID: 16790698 Free article. Clinical Trial.

5

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. Tashkin DP, et al. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5. N Engl J Med. 2008. PMID: 18836213 Free article. Clinical Trial.

6

Benefit:Risk Profile of Budesonide in Obstructive Airways Disease.

Tashkin DP, Lipworth B, Brattsand R. Tashkin DP, et al. Drugs. 2019 Nov;79(16):1757-1775. doi: 10.1007/s40265-019-01198-7. Drugs. 2019. PMID: 31549299 Free PMC article. Review.

7

Marijuana and Lung Disease.

Tashkin DP. Tashkin DP. Chest. 2018 Sep;154(3):653-663. doi: 10.1016/j.chest.2018.05.005. Epub 2018 May 17. Chest. 2018. PMID: 29778658 Review.

8

The use of nebulized pharmacotherapies during the COVID-19 pandemic.

Sethi S, Barjaktarevic IZ, Tashkin DP. Sethi S, et al. Among authors: tashkin dp. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620954366. doi: 10.1177/1753466620954366. Ther Adv Respir Dis. 2020. PMID: 33167796 Free PMC article. Review.

9

Inhaled Marijuana and the Lung.

Tashkin DP, Tan WC. Tashkin DP, et al. J Allergy Clin Immunol Pract. 2022 May 21:S2213-2198(22)00495-0. doi: 10.1016/j.jaip.2022.05.009. Online ahead of print. J Allergy Clin Immunol Pract. 2022. PMID: 35609784

10

Vaping Cannabis and Chronic Obstructive Pulmonary Disease.

Tashkin DP. Tashkin DP. Ann Am Thorac Soc. 2018 Oct;15(10):1137-1138. doi: 10.1513/AnnalsATS.201807-463ED. Ann Am Thorac Soc. 2018. PMID: 30272498 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results